Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

Klaria Pharma Holding AB: Klaria Interim Report Q3 2023

Klaria Pharma Holding
Download udgivelse

1 July - 30 September 2023

Summary of the Interim Report

Net sales of 0.6 MSEK (0.0 MSEK)

Other income amounted to 0.0 MSEK (0.0 MSEK)

Third quarter of 2023

- R&D costs for the period amounted to 7.4 MSEK (10.9 MSEK)

- Profit after tax amounted to -10.8 MSEK (16.1 MSEK) ∞ Earnings per share for the quarter amounted to -0.10 SEK (-0.27 SEK)

- Cash flow from operating activities amounted to -7.3 MSEK (-3.6 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 2.3 MSEK (6.7 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 50.7 MSEK (39.3 MSEK)

The period January-September 2023

- Net sales of 7.1 MSEK (3.7 MSEK)

- Other income amounted to 0.3 MSEK (0.4 MSEK)

- R&D costs for the period amounted to 23.0 MSEK (42.7 MSEK)

- Profit after tax amounted to -26.3 MSEK (-50.9 MSEK)

- Earnings per share for the quarter amounted to -0.27 SEK (-0.88 SEK)

- Cash flow from operating activities amounted to -18.6 MSEK (-39.1 MSEK)

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.